TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04772352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat treatment
Description: According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention
Description: According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Study: NCT05843344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block with a combination of ropivacaine and dexmedetomidine
Description: Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +0.5 mcg/kg (1mL) of dexmedetomidine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 200 mcg of dexmedetomidine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block with ropivacaine only
Description: Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +1 mL of normal saline will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 3 mL of normal saline will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
Study: NCT04747054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
Study: NCT06330298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment social cognition and emotion regulation (T-ScEmo)
Description: T-ScEmo is a multifaceted treatment protocol that has the overall aim to improve social cognition, regulation of social behaviour and social participation in everyday life (Westerhof et al., 2017; 2019). The treatment includes, in addition to practicing social cognitive skills throughout the treatment, close involvement of a significant other, and homework assignments. The treatment consists of three modules that address 1) perception of social information including facial expressions of emotions, 2) perspective taking and understanding of social information and 3) regulation of social behaviour. The treatment contains 15-one hour live treatment sessions with a neuropsychologist and 5 online practice sessions, once or twice a week. In the online sessions, the patient can practice the information at home as a neuropsychologist is available for questions. When patients find it too difficult to practice individually at home, there is a opportunity to offer these sessions as live sessions
Study: NCT05359536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Early Childhood educators in PA
Description: The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
Study: NCT05708365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Lung Protective Ventilation
Description: ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-Lung Protective Ventilation
Description: ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute
Study: NCT04235361

Intervention type: DIAGNOSTIC_TEST
Intervention: Differential RPA tests
Description: The mobile diagnostic suitcases will be deployed at Ebola Treatment centres in DRC. Samples of patients refered for diagnostic testing will be tested by PCR by existing diagnostic teams, and will be additionally tested by the mobile suitcase laboratory using differential RPA tests for 6 parameters.
Study: NCT04814706

Intervention type: DIETARY_SUPPLEMENT
Intervention: Carbohydrate drinking
Description: Administration of carbohydrate fluid
Study: NCT04589832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-1
Description: Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
Study: NCT06026800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-R01
Description: Personalized mRNA vaccine encoding neoantigen, IH injection
Study: NCT04747054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Loco-regional radiotherapy
Description: Depending on the choice of radiotherapy timing:~* Before 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time between one week after the first administration of pembrolizumab and the first day of the 3rd cycle.~* After 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time after 3rd cycle (C3D1) and up to a maximum of 4 weeks after the 6th cycle of pembrolizumab.~Dose/fraction of radiotherapy: 54 Gy/18 fractions (recommended schedule) or 70Gy/33-35 fractions or other curative dose/fraction schedules with shorter duration and biologically equivalent dose of at least 60Gy at the discretion of local investigators, in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary. Other cycles of pembrolizumab will be administered during and after radiotherapy.
Study: NCT05691842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT intervention
Description: Patients will perform a muscle strength training circuit interspersed with resistance training circuit. The strength training circuit will consist of 10 strength exercises and resistance training circuit will consist of walking, jogging and running exercises. Each exercise will be performed for one minute, trying to reach maximum intensities adapted to each individual's condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task intervention
Description: Dual task training will consist of the progressive and specific assignment of primary motor tasks and secondary motor or cognitive tasks focused on: i) Primary tasks: static, dynamic balance and gait exercises; ii) Secondary tasks (motor or cognitive): verbal fluency, mathematical calculation, memory, visual-spatial planning, auditory discrimination, fine motor task, motor transport task.
Study: NCT05603182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA052
Description: PRA052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA052
Description: PRA052

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04747054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles
Study: NCT05719350

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises for Knee
Description: Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises for Knee
Description: Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
Study: NCT06151613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous eCTG monitoring using the NFMS
Description: Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
Study: NCT05027776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses Group among 9-14 years
Description: Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses Group among 9-19 years
Description: Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3-doses Group among 20-26 years
Description: Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
Study: NCT05098249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verum
Description: The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.
Study: NCT04809649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole
Description: Participant will receive treatment with SUBA-itraconazole
Study: NCT06177223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral therapy
Description: CBT-based treatment plan would be designed to address PTSD and associated problems.
Study: NCT06153628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Videos consisting of nature and undersea images will be played through virtual reality glasses, which the woman wants to watch and can change whenever she wants.
Study: NCT06432491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking cold water
Description: Volunteers in the intervention group will be asked to drink up 500 ml 4℃ water within 10 minutes four times per day throughout the study.
Study: NCT04759612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Participants will watch an upper extremity functionality test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Participants will watch an upper extremity functionality test.
Study: NCT05310968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban hydrochloride sodium chloride injection
Description: Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirofiban hydrochloride sodium chloride injection placebo
Description: Day 1: Tirofiban placebo will be injected at the same rate with experimental group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
Study: NCT04815512

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests.
Description: serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests.
Description: serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.

Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function tests
Description: creatinine , urea and serum uric acid will be analysed in the serum.

Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function tests
Description: creatinine , urea and serum uric acid will be analysed in the serum.
Study: NCT05750056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentail 0.1 ug/kg was administered for sedation induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Sufentail 0.1 ug/kg was administered for sedation induction.
Study: NCT06523764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegoprazan
Description: tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bismuth potassium citrate
Description: bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin
Description: bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
Study: NCT05965050

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Myofascial Release Technique
Description: myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Therapy
Description: Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
Study: NCT04090515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: This intervention involves a one-hour group meeting for six consecutive weeks.
Study: NCT06385379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system
Description: The WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system, the aortic extension stent graft system and the branch stent system.
Study: NCT06195306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Undergo mammography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Undergo mammography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-Acid Ethyl Esters
Description: Given PO
Study: NCT04090515

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Video Control
Description: This intervention involves a one-hour educational video control viewing for six consecutive weeks.
Study: NCT06195306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Random Periareolar Fine-Needle Aspiration
Description: Undergo RPFNA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Random Periareolar Fine-Needle Aspiration
Description: Undergo RPFNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO
Study: NCT00944593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jejunal Feed
Description: Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 200ml Normal Saline 0.9%
Study: NCT05254912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Bemotrizinol in sunscreen formulation
Description: 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Bemotrizinol in petrolatum
Description: 6% Bemotrizinol (BEMT) as a dispersion in petrolatum (SU-E-101413-82)

Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle
Description: Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91)
Study: NCT04820049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F573
Description: F573 for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water for injection